Monday June 26th 2017

Posts Tagged ‘Paolo Zamboni’

MS patients fight for access to new ‘Zamboni’ treatment

MS patients fight for access to new ‘Zamboni’ treatment

A month after Italian vascular surgeon Dr. Paolo Zamboni’s controversial report on treating multiple sclerosis made headlines in November 2009, an elated Jamie Chalmers went to his neurologist and handed him a stack of print-outs on the new findings. Without so much as a [Read More]

Video: Omar Majdi CCSVI Treatment in Bulgaria

Video: Omar Majdi CCSVI Treatment in Bulgaria

Omar’s CCSVI Treatment in Tokuda Hospital, Bulgaria – 11 June 2010 [Read More]

Plight of MS patients exposes flaws in Canada’s approach to medical research

Plight of MS patients exposes flaws in Canada’s approach to medical research

Diana Gordon travelled to the United States earlier this month to have a new MS treatment touted by Italian doctor Paolo Zamboni. After the procedure, which opens up blocked or malformed veins, the Barrie, Ont., woman said she has noticed several improvements in her health, [Read More]

 Page 3 of 10 « 1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]